However, Antonia et al.14have pointed out that patients using CTLA‐4 inhibitor and PD‐1/PD‐L1 inhibitor together are more likely to have treatment‐related AEs and higher grades of adverse reactions, and the incidence and severity of MG may also be higher. The gene discussed is CTLA4; the disease is myasthenia gravis.